2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Multiple Myeloma
2
Waldenstrom Macroglobulinemia
1
Solid Tumor
1
Recurrence
1
Lymphoma, Follicular
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Interventions
pembrolizumab
14
Injections
13
Paclitaxel
10
Nivolumab
10
Docetaxel
9
Cisplatin
9
Capecitabine
9
Bevacizumab
8
toripalimab
7
senaparib
7
Fluorodeoxyglucose F18
7
Cyclophosphamide
7
tislelizumab
6
atezolizumab
6
Irinotecan
6
Fluorouracil
6
Gemcitabine
5
fludarabine
4
apatinib
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Carboplatin
4
spartalizumab
3
sintilimab
3
pertuzumab
3
olaparib
3
camrelizumab
3
Rifampin
3
Radiosurgery
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Solid Tumor
×
ulocuplumab
×
Clear all
NCT02472977
2018-11-01
CXCessoR4
Bristol-Myers Squibb
Phase 1/2
Terminated
61 enrolled
11 charts